Laura Sepp-Lorenzino, PhD

At-Large Director (2025-2028)

Laura Sepp-Lorenzino, Ph.D. is Scientific Advisor, Executive Vice President and former Chief Scientific Officer at Intellia Therapeutics, a leading clinical-stage genome editing company developing novel, potentially curative medicines leveraging CRISPR-based technologies.

Before joining Intellia, Laura was VP, Head of Nucleic Acid Therapies and member of the External Innovation team at Vertex Pharmaceuticals, with previous positions as VP and entrepreneur-in-residence at Alnylam Pharmaceuticals, Inc., and Executive Director RNA Therapeutics at Merck & Co., Inc. In addition to her extensive experience in nucleic acid therapies, Laura has expertise in oncology drug discovery and development acquired earlier in her career by leading the Cancer Research Department at Merck West Point and working as an assistant attending molecular biologist at Memorial Sloan-Kettering Cancer Center.

She received her professional degree in Biochemistry from the University of Buenos Aires, Argentina and both her M.S. and Ph.D. in Biochemistry from New York University. In addition to ASGCT, Laura is a member of the board of directors of Taysha Gene Therapies, AskBio Biopharmaceutical, Inc., Sail Medicines, and the Alliance for Regenerative Medicine. She chairs the scientific advisory board of Travin Bio, and is an SAB member of Thermo Fisher Scientific, the U.K. Nucleic Acid Therapy Accelerator, and Arsenal Capital Partners. Laura is on the editorial boards of Nucleic Acid Therapeutics and Molecular Therapy Nucleic Acids.